The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Optimizing precision medicine in NSCLC
Liza Villaruz, MD, University of Pittsburgh, Pittsburgh, PA, describes strategies to improve outcomes in metastatic non-small cell lung cancer (NSCLC). Whilst targeted therapies have had a profound effect on the treatment landscape, demographic disparities in next generation sequencing (NGS) remain a hurdle. By providing equitable care, patient outcomes can be optimized by receiving therapies that target relevant oncogenic drivers. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL
